23andMe Granted First FDA Authorization for Direct-to-Consumer Genetic Test on Cancer Risk – 23andMe Media Center

Authorization allows 23andMe to report on BRCA1- and BRCA2-related genetic risk for breast, ovarian and prostate cancer

23andMe, Inc., the leading personal genetics company, today received the first-ever FDA authorization for a direct-to-consumer genetic test for cancer risk. The authorization allows 23andMe to provide customers, without a prescription, information on three genetic variants found on the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian and prostate cancer.

Source: 23andMe Granted First FDA Authorization for Direct-to-Consumer Genetic Test on Cancer Risk – 23andMe Media Center